Skip to main content
Signal8

CERO THERAPEUTICS HOLDINGS, INC. (CERO) Form 10-Q — May 15, 2026

$CEROForm 10-QFiled May 15, 2026, 4:12 PM ET0001213900-26-057753Original filing

Cero Therapeutics Holdings reported a net loss of $5.9 million for the three months ended March 31, 2026, driven by $4.8 million in operating expenses and $896,722 in derivative expenses related to new convertible debt. The company holds only $857,489 in cash and equivalents against a working capital deficit of approximately $9.8 million and an accumulated deficit of $96.7 million. The filing includes explicit going-concern language, stating that these conditions raise substantial doubt about the company’s ability to continue as a going concern within one year from the date of issuance.

Key figures

Total Debt
136765
Debt Amount
1875000
Cash Position
857489
Interest Rate
10
Maturity Date
July 9, 2027
Shares Outstanding
45112406
Ga Expenses
2507383
Rd Expenses
2338345
Operating Expenses
4845728
Derivative Liabilities
2396722
Net Cash Used In Operations
2800000

Price after filing

1 day: 0.0%7 days: -22.9%30 days: -58.6%

Close on the filing date to close N calendar days later (from $0.03). Historical, not a forecast.

AI analysis

Red flags6 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.